Diversifying Cord Blood Banking through Adipose-Derived Stem Cell Storage

The global cord blood banking industry has been rapidly maturing in recent years. In part, this has been caused by changes in processing, storage, and transplantation technologies. These changes require executives and industry decision-makers to have a firm understanding of emerging trends.

One of the most notable cord blood industry trends has been a diversification of services. Put simply, cord blood banks are becoming diversified stem cell biobanks.

Cord blood banks worldwide have started to incorporate the storage of:

• umbilical cord tissue
• placental blood and tissue
• amniotic fluid
• menstrual fluid
• dental pulp stem cells
• adipose tissue
• peripheral blood

Because cord blood banking is a niche service, there are several benefits to diversifying into related areas of stem cell storage. These include but are not limited to increased revenue, diversification, up-selling / cross-marketing opportunities, and cost efficiencies.

American Cryostem, an Adipose-Derived Stem Cell Storage Company

American Cryostem is an American-based company that offers cord blood banks the opportunity to license their proprietary adipose-derived stem cell technologies.

Specifically, they  allow companies to license their adipose-derived stem cell :

• processing technologies
• storage platform technologies
• expansion and differentiation services
• marketing materials

This allows third-party partners (cord blood banks) to quickly and cost-effectively integrate this service.

Importantly, American Cryostem grants only one exclusive license per region. Thus, if a license is available for your region, a partnership of this nature could be an efficient way to add adipose-tissue storage as a “bolt-on” service.

To learn more about emerging trends and opportunities, view the “Global Cord Blood Banking Industry Report 2020.”

About BioInformant

BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.